The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.
The sBLA submission included results from the randomized, parallel-arm, placebo-controlled and active-controlled trial foresiGHt.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback